prompt1 : extract information from  breast pathology report. List the histological classification, i.e. type of cancer or DCIS, subtype, description of any necrosis, any mention of tumor infiltrating lymphocytes,  histological grade, nuclear grade,  lymphovascular invasion, calcification, receptor status, IHC and any other ancillary testing results.  List out and expand the main points.
prompt2 : The report is - Subtype LumA, SURG PATH #: SPECIMEN CLASS: ALT ID #: SEX: F. DATE RECEIVED: DATE OF PRINTING: Material Received: A: left breast SLN #1 time out. B: left breast SLN #2 time out. C: left breast SLN #3 time out. D: left breast SLN #4 time out. E: left breast lumpectomy time out. F: additional anterior left breast tissue. History: year-old female with history of invasive lobular carcinoma of the breast. Final Diagnosis: A. Lymph node (1), "left breast SLN #1", biopsy: There is no evidence of malignancy in one lymph node. (0/1). Deeper sections and a pancytokeratin immunostain are negative in support of the above diagnosis. B. Lymph node (1), "left breast SLN #2", biopsy: There is no evidence of malignancy in one lymph node. (0/1). Deeper sections and a pancytokeratin immunostain are negative in support of the above diagnosis. C. Lymph node (1), "left breast SLN #3", biopsy: There is no evidence of malignancy in one lymph node. (0/1). Deeper sections and a pancytokeratin immunostain are negative in support of the above diagnosis. D. Lymph node (1), "left breast SLN #4", biopsy: There is no evidence of malignancy in one lymph node. (0/1). Deeper sections and a pancytokeratin immunostain are negative in support of the above diagnosis. E. Breast, "left breast lumpectomy", lumpectomy: Invasive lobular carcinoma, moderately differentiated. See comment. Lobular carcinoma in-situ and atypical lobular hyperplasia. Previous biopsy site changes. F. Breast, "additional anterior left breast tissue", excision: Microscopic focus of invasive lobular carcinoma. See comment. Lobular carcinoma in-situ and atypical lobular hyperplasia. Date of Printing: SURG PATH #: ALT ID #: Comment: INVASIVE CARCINOMA OF THE BREAST. Specimen Type: Lumpectomy. Laterality: Left. Tumor Site: 1:00, 6 cm FTN. Histologic Type: Invasive lobular carcinoma. Size of Invasive Component: 1.5 cm in greatest dimension in the main lumpectomy. 0.3 cm in greatest dimension in the separately. submitted "additional anterior left breast tissue". Tumor Multicentricity: Yes. Surgical Margins: The carcinoma is focally 1.5 mm from the anterior margin and focally 1.75 mm from the inferior margin in. the. main lumpectomy (Specimen E); all other margins are greater than 0.2 cm away. In specimen F ("additional anterior left breast. tissue") which is unoriented, carcinoma is present at one shave margin/tissue edge while all other margins are 0.2 cm or greater. away. Histologic Grade (Nottingham Histologic Score): II/III. Tubule Formation: 3. Nuclear Grade: 2. Mitotic Count (40x objective): 1. Total Nottingham Score: 6/9. Ductal Carcinoma In-situ (DCIS): Absent. Lobular Carcinoma In-situ (LCIS): Present. Lymph-Vascular Invasion: Not identified. Perineural Invasion: Not identified. Tumor Necrosis: Absent. Nipple Involvement: Not applicable. Skin Involvement: Not applicable. Lymph Node Sampling: Sentinel lymph node(s) only. Total number of involved nodes/total nodes found: 0/4. Non-neoplastic Breast Tissue: Focal atypical ductal hyperplasia. Fibrosis and prior biopsy site changes. Prognostic markers: Ordered on prior biopsy. See. for addendum. Time between tumor removal and placement into formalin < 1 hour: Yes. Fixation Time between 6-48 hours: Yes. Pathologic Staging: pT1c snNo(i-). Primary Tumor (Invasive Carcinoma) (pT). pT1c: Tumor 10 mm but d20 mm in greatest dimension. Regional Lymph Nodes (pN). Modifier (required only if applicable). (sn): Only sentinel node(s) evaluated. If 6 or more sentinel nodes and/or nonsentinel nodes are removed, this modifier. should not be used. pNO (i-): No regional lymph node metastases histologically, negative IHC. Distant Metastasis (M). Not applicable. The pathologic stage assigned here should be regarded as provisional, as it reflects only current pathologic data and does not. incorporate full knowledge of the patient's clinical status and/or prior pathology. In Specimen F, immunohistochemical stain for smooth muscle myosin supports the diagnosis. Attestation: By this signature, I attest that I have personally formulated the final interpretation expressed in this report and that the above diagnosis is based. upon my examination of the slides and/or other material indicated in this report. Interpreted by: Date of Printing: SURG PATH #: ALT ID #: Resident. Gross Description: A. Received in formalin labeled with the patient's name "left female breast sentinel lymph node #1 out at. are two tan-pink. lymph nodes measuring 0.9 x 0.9 x 0.6 cm and 1.4 x 1.3 x 0.6 cm. The smaller lymph node is inked black. Both lymph nodes are. serially sectioned and submitted entirely in cassette A1. B. Received in formalin labeled with the patient's name "female left breast sentinel lymph node #2 time out. " is a 2.3 x 1.8 x. 0.6 cm aggregate of yellow-tan fibroadipose tissue that is palpated to reveal two possible lymph nodes measuring 1.2 x 0.8 x 0.4. cm and 1.5 0.7 x 0.5 cm. The smaller lymph node is inked black. Both lymph nodes are serially sectioned and submitted. entirely in cassette B1. C. Received in formalin labeled with the patient's name and "female left breast sentinel lymph node #3 time out. " is a 3.2 x. 1.7 x 0.9 cm aggregate of yellow-tan fibroadipose tissue that is palpated to reveal two possible fymph nodes measuring 0.5x 0.5. x. 0.3 cm and 1.0 x 0.6 x 0.4 cm. The smaller lymph node is inked black. Both lymph nodes are serially sectioned and. submitted. entirely in cassette C1. D. Received in formalin labeled with the patient's name and "left female breast sentinel lymph node #4 out at. ". is a 2.2 X 1.1. x 0.8 cm aggregate of yellow-tan fibroadipose tissue that is palpated to reveal one possible lymph node measuring 0.4 x 0.3 x 0.3. cm. The specimen is serially sectioned and submitted entirely in cassette D1. E. Received fresh labeled with the patient's information and "female left breast lumpectomy" is a 35 gm lumpectomy specimen. measuring 7.0 x 5.5 x 1.0 cm. The specimen has already been inked by the surgeon as follows: Orange - Lateral. Yellow - Medial. Red - Superior. Blue - Inferior. Green - Anterior. Black - Posterior. The specimen is serially sectioned from lateral to medial into twelve slices. In slices 6 through 8, there is a 1.2 x 0.7 x 0.6 cm firm. white well circumscribed mass that is: 0.1 cm from the anterior margin. 1.8 cm from the posterior margin. 1.5 cm from the superior margin. 2.2 cm from the inferior margin. 2.0 cm from the lateral margin. 1.6 cm from the medial margin. The remainder of the breast parenchyma is yellow-white adipose tissue. The specimen is entirely submitted as follows: E1. Slice #1 (lateral margin). E2. Slice #2. E3-4. Slice #3 bisected. E5-7. Slice #4 trisected. E8-9. Slice #5 bisected. E10-12. Slice #6 trisected. E13-14. Slice #7 bisected. E15-17. Slice #8 trisected. E18-20. Slice #9 trisected. E21-22. Slice #10 bisected. E23-24. Slice #11 bisected. E25. Slice #12 (medial margin). The specimen was removed from the patient at. and placed in formalin at. on and not removed from formalin until. F. Received in formalin labeled with the patient's name and "additional anterior left breast tissue" is a 2.7 x 1.9 x 1.0 cm piece of. yellow lobular adipose tissue. The outer surface is inked black. The specimen is serially sectioned to reveal a yellow. homogeneous cut surface with no discrete lesion or abnormalities identified. The specimen is entirely submitted in cassettes. Date of Printing: SURG PATH #: ALT ID #: F1-F3. The breast was removed from the patient at. , and placed in formalin immediately in the OR and not removed from. formalin until. on today's date. If immunohistochemical stains and/or in situ hybridization are cited in this report, the performance characteristics were determined by the. in compliance with CLIA'88. regulations. Some of these tests rely on the use of "analyte specific reagents" and are subject to specific labeling requirements by the FDA. Known. positive and negative control tissues demonstrate appropriate staining. This testing was developed by the. It has not been cleared or approved by the FDA. The FDA has determined that such clearance or approval. is not necessary. Date of Printing:

expanded version (tokens=2537) : 
 The main points extracted from the report are as follows:

- Subtype: LumA
- Histological classification: Invasive lobular carcinoma with lobular carcinoma in-situ and atypical lobular hyperplasia.
- Size of invasive component: 1.5 cm in greatest dimension in the main lumpectomy and 0.3 cm in greatest dimension in the separately submitted additional anterior left breast tissue.
- Tumor Multicentricity: Yes
- Histologic Grade: II/III with a total Nottingham score of 6/9. Tubule formation was 3 and nuclear grade was 2.
- Lymphovascular invasion: Not identified
- Tumor Necrosis: Absent
- Calcification: Not mentioned
- Receptor status: Not mentioned in this report
- IHC and ancillary testing results: Immunohistochemical stain for smooth muscle myosin supports the diagnosis. Prognostic markers were ordered on the prior biopsy, and the report mentions an addendum with the results of those tests. 

In addition, the report details the findings of lymph node biopsies, non-neoplastic breast tissue, and provides information on surgical margins and pathologic staging. It also includes gross descriptions of the specimens received and processed.

prompt : Please generate a succinct report in 75 words from the above information. Exclude any filler words or sentences. If something is not mentioned or specified, exclude it from the report. Low verbosity.

final output (tokens=2698) : 
 Final Diagnosis: Left breast lumpectomy and additional anterior tissue reveals invasive lobular carcinoma, moderately differentiated with lobular carcinoma in-situ and atypical lobular hyperplasia. No lymphovascular invasion or tumor necrosis identified. Nottingham histologic score of II/III with total Nottingham score of 6/9. Sentinel lymph nodes negative for malignancy. Prognostic markers and receptor status not mentioned in this report. Caution should be exercised as pathologic staging, based only on current data, may not reflect the patient's full clinical status.

